Zenas BioPharma, Inc. Common Stock (ZBIO) is a publicly traded Healthcare sector company. As of May 19, 2026, ZBIO trades at $17.71 with a market cap of $1.16B and a P/E ratio of -1.38. ZBIO moved -7.96% today. Year to date, ZBIO is -50.99%; over the trailing twelve months it is +61.51%. Its 52-week range spans $5.83 to $44.60. Analyst consensus is strong buy with an average price target of $43.67. Rallies surfaces ZBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes ZBIO SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $17.71 |
| Market Cap | $1.16B |
| P/E Ratio | -1.38 |
| EPS | $-11.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.60 |
| 52-Week Low | $5.83 |
| Volume | 1.13K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.00M |
| Net Income | $-156.99M |
| Gross Margin | 0.00% |
6 analysts cover ZBIO: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $43.67.